home / stock / xrtx / xrtx news

XRTX News and Press, XORTX Therapeutics Inc. From 05/04/23

Stock Information
Company Name: XORTX Therapeutics Inc.
Stock Symbol: XRTX
Market: NASDAQ
Website: xortx.com
Menu
XRTX XRTX Quote XRTX Short XRTX News XRTX Articles XRTX Message Board
Get XRTX Alerts

News, Short Squeeze, Breakout and More Instantly...
XRTX - XORTX Therapeutics' Xorlo eligible for accelerated approval, confirms FDA

2023-05-04 10:04:37 ET XORTX Therapeutics ( NASDAQ: XRTX ) announced a positive outcome of their recent Type D meeting with the U.S. Food and Drug Administration regarding the accelerated approval of XORLO as a treatment for autosomal dominant polycystic kidney disease ((ADPKD). T...
XRTX - FDA Confirms Eligibility of XORLO(TM) for Accelerated Approval

CALGARY, Alberta, May 04, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“ XORTX ” or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive ...

XRTX - Xortx stock climbs on FDA orphan drug status for kidney disease therapy

2023-04-21 07:25:44 ET The U.S. Food and Drug Administration (FDA) granted orphan drug designation to Xortx Therapeutics' ( NASDAQ: XRTX ) Xorlo (oxypurinol) to treat autosomal dominant polycystic kidney disease (ADPKD). Polycystic kidney disease is an inherited disord...

XRTX - XORTX Announces Receipt of FDA Orphan Drug Designation to Treat Autosomal Dominant Kidney Disease

CALGARY, Alberta, April 21, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disea...
XRTX - XORTX Announces Type D Meeting with FDA to be held May 1, 2023

● Type D Meeting Requested to Accelerate XRx-008 Clinical Program ● CALGARY, Alberta, March 14, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company ...

XRTX - XORTX Provides Update on 2022 Achievements and 2023 Planned Milestones

CALGARY, Alberta, Feb. 07, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney diseas...

XRTX - Xortx stock rises on FDA filing for orphan drug status for kidney disease therapy

Xortx Therapeutics ( NASDAQ: XRTX ) said it submitted an orphan drug designation (ODD) request to the U.S. Food and Drug Administration (FDA) for XRx-008 program to treat Autosomal Dominant Polycystic Kidney Disease (ADPKD). The FDA grants orphan drug status to therapies which treat o...
XRTX - XORTX Announces Submission of Orphan Drug Designation Request for XRx-008 Program to Treat Autosomal Dominant Kidney Disease

CALGARY, Alberta, Feb. 01, 2023 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (" XORTX " or the “ Company ”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney diseas...

XRTX - Why Is Xortx Therapeutics (XRTX) Stock Up 30% Today?

InvestorPlace - Stock Market News, Stock Advice & Trading Tips There’s great news circulating about Xortx Therapeutics (NASDAQ: XRTX ) today. In a clinical study, XORLO, Xortx’s orally administered brand of oxypurinol, demonstrated a “substantial increase” ...

XRTX - Xortx stock surges ~60% as potential kidney disease drug shows promise in early stage study

Xortx Therapeutics ( OTCQB:XRTXF ) ( NASDAQ: XRTX ) reported data from a bridging pharmacokinetics trial of its proprietary formulation of oral oxypurinol, Xorlo, being explored for kidney disease. The company said data from the study, dubbed XRX-OXY-101, showed that Xorl...
Previous 10 Next 10